Hepatitis c virus and human immunodeficiency virus: Clinical issues in coinfection

American Journal of Medicine

Volumn 107, Issue 6 SUPPL. 2, 1999, Pages 79-84

  Dieterich, Douglas T ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; PROTEINASE INHIBITOR; RIBAVIRIN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONFERENCE PAPER; DISEASE COURSE; DRUG RESISTANCE; GENOTYPE; HEMOPHILIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER TOXICITY; MIXED INFECTION; MORTALITY; PRIORITY JOURNAL; VIRUS LOAD;

EID: 0033378309     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(99)00390-3     Document Type: Conference Paper

References (56)

1. Wu J.S., Lu C.F., Liu W.T., Lin S.Y. Prevalence of antibodies to hepatitis C virus (anti-HCV) in different populations. Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chi. 24:1991;55-60.
2. Abe K., Naito H., Kurata T., et al. Prevalence of HCV and HGV in patients infected with HIV isolation of a new HGV genotype . Hepatology. 28:1998;702A. AASLD abstract.
3. th Annual Meeting, 11/12-15, 1998, Denver, CO.
4. Rathi P.M., Amarapurkar D.N., Borges N.E., et al. Spectrum of liver diseases in HIV infection. Indian J Gastroenterol. 16:1997;94-95.
5. Richard L., Pellegrin J.L., Barbeau P., Brossard G., Leng B., Fleury H.J. HIV-1 and HCV co-infected patients detection of active viral expression using a nested polymerase chain reaction . Mol Cell Probes. 1993;7405-7410.
6. Monga H.K., Breauz K., Rodriques-Barradas MC, Yoffe B. Increased HCV-related morbidity and mortality in HIV patients. Hepatology. 28:1998;565A. Abstract.
7. Sulkowski MS. Hepatitis C virus and HIV co-infection: a sleeping giant wakes. The Hopkins HIV Report 1999(January):3-12.
8. Zylberberg H., Landau A., Chaix M.L., et al. Ribavirin does not modify HIV replication in HIC-HIV coinfected subjects under antiretroviral regimen. Hepatology. 28:1998;479A. Abstract.
9. Moretti, F, Novati R, Morsica G, Poli G, Lazzarin A. Chronic active hepatitis and liver cirrhosis are crucial complications in long-term survivors of HIV infection. Presented at the 12th World AIDS Conference, 6/28-7/2, 1998, Geneva. Abstract.
10. th World AIDS Conference, 6/28-7/2, 1998, Geneva. Abstract.
11. Hasaio CB, Draw A, Hewett RG, Shelton MJ, Rich G. Protease inhibitors and liver transaminase enzyme in patients co-infected with HIV and hepatitis C virus (HCV). Presented at the 38th ICAAC annual meeting of the American Society for Microbiology, 9/24-27/1998, San Diego, CA. Abstract.
12. Murill C, Weeks HR, Lambert S, et al. Age-specific trends in seroprevalence of HIV and hepatitis B and C virus among injection drug users admitted to drug treatment in six U.S. cities. Presented at the 12th World AIDS Conference, 6/28-7/2, 1998, Geneva. Abstract.
13. Rockstroh J, Spengler U, Kaiser R, et al. Effect of HIV-infection on hepatitis C virus (HCV)-infection in hemophiliacs and i.v. drug users. Presented at the 12th World AIDS Conference, 6/28-7/2, 1998, Geneva. Abstract.
14. Serfaty L, Costagliola D, Wendum D, et al. Does HIV infection aggravate chronic hepatitis C in IV drug users? A case-control study. Hepatology.1998;Oct:462A. Abstract.
15. Garcia-Samaniego J, Soriano V., Castilla J., et al. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. The hepatitis/HIV Spanish study group. Am J Gastroenterol. 92:1997;1130-1134.
16. Hanley J.P., Jarvis L.M., Andrews J., et al. Investigation of chronic hepatitis C infection in individuals with haemophilia assessment of invasive and non-invasive methods . Br J Haematol. 94:1996;159-165.
17. Thomas Sl, Newell M.L., Peckham C.S., Ades A.E., Hall A.J. A review of hepatitis C virus (HCV) vertical transmission risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection . Int J Epidemiol. 27:1998;108-117.
18. Granovsky M.O., Minkoff H.L., Tess B.H., et al. Hepatitis C virus infection in the mothers and infants cohort study. Pediatrics. 102:1998;355-359.
19. Ruiz-Chercoles E, Ramos JT, Ruiz-Contreras J, et al. Vertical transmission of hepatitis C in children born to HIV-infected mothers. Presented at the 12th World AIDS Conference, 6/28-7/2, 1998, Geneva. Abstract.
20. Lasarte J.J., Garcia-Granero M., Lopez A., et al. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology. 28:1998;815-822.
21. Thursz M.R., Hill A.V., Trepo C., Thomas H.C. Polymorphisms in genes affecting TH1/TH2 balance influence the outcome of HBV and HCV infection. Hepatology. 28:1998;565A. Abstract.
22. Kissinger G.L., Stachowski J., Pollok M., et al. Effects of INF-α therapy compted to combined therapy with ribavirin/INF-α on cytokine profiles, natural killer cell activity and costimulatory molecule expression in patients with chronic hepatitis. Hepatology. 28:1998;565A. Abstract.
23. Woitas RP, Rockstroh JK, Theisen A, Spengler U. HIV-infection alters T cell immune response to hepatitis C virus antigens. Presented at the 12th World AIDS Conference, 6/28-7/2, 1998, Geneva. Abstract.
24. Quan C.M., Krajden M., Grigoriew G.A., Salit I.E. Hepatitis C virus infection in patients infected with the human immunodeficiency virus. Clin Infect Dis. 17:1993;117-119.
25. Haydon G.H., Flegg P.J., Blair C.S., et al. The impact of chronic hepatitis C virus infection on HIV disease and progression in intravenous drug users. Eur J Gastroenterol Hepatol. 10:1998;485-489.
26. Piroth L., Duong M., Quantin C., et al. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? AIDS. 12:1998;381-388.
27. Hatzakis A, Touloumi G, Karafoulidou A, et al. Hepatitis C virus (HCV) genotypes and progression of HIV infection in hemophiliacs. Presented at the 12th World AIDS Conference, 6/28-7/2, 1998, Geneva. Abstract.
28. Hoffman-Terry M, Gupta AK, Wasser TE. The correlation between HIV and hepatitis C co-infection: a case control study. Presented at the 12th World AIDS Conference, 6/28-7/3, 1998, Geneva. Abstract.
29. Sabin C.A., Telfer P., Phillips A.N., Bhagani S., Lee C.A. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis. 175:1997;164-168.
30. Gavazzi G., Richallet G., Morand P., et al. Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV. Pathol Biol. 46:1998;412-415.
31. Rutschmann O.T., Negro F., Hirschel B., et al. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis. 177:1998;783-785.
32. Mendel I, Froment L. Lack of activity of the protease inhibitors on the hepatitis C virus replication in HIV-coinfected patients. Presented at the 38th ICAAC annual meeting of the American Society for Microbiology, 9/24-27, 1998, San Diego, CA. Abstract.
33. Bernard L, Matsiota-Bernard P, Bani-Sadr F, et al. Influences of HIV protease inhibitors on hepatitis C viral (HCV) load and serum alanine aminotransferase (s-ALT) in patients with HIV and HCV coinfection. Presented at the12th World AIDS Conference, 6/28-7/3, 1998, Geneva. Abstract.
34. Perez-Cano R, Giron JA, Fernandez C, et al. Evolution of hepatitis C virus load in relationship of HIV viral load in patients who responded to antiretroviral therapy. Presented at the 38th ICAAC annual meeting of the American Society of Microbiology, 9/24-27, 1998, San Diego, CA. Abstract.
35. Rutschmann OT, Hirschel B, Negro F, Perrin LH. Lack of effect of long-term HAART on hepatitis C (HCV) viremia. Presented at the 12th World AIDS Conference, 6/28-7/3, 1998, Geneva. Abstract.
36. Mina J., Flexman J., French M.A.H. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors an immune restoration disease? AIDS. 12:1998;229-2293.
37. Orenstein R, Stewart M. Drug-induced hepatitis in the era of HAART.Presented at the 38th ICAAC annual meeting of the American Society for Microbiology, 9/24-27, 1998, San Diego, CA. Abstract.
38. Lynn WA, Ash S. Deterioration in liver functin following initiation of highly activty anti-retroviral therapy (HAART). Poster presented at the IDSA 36th Annual Meeting, 11/12-15, 1998, Denver, CO.
39. Pilaouz G, Landau A, Eliaszewicz M, et al Rapidly evolving hepatitis C virus infection in HIV coinfected patients treated with HAART. Presented at the 12th World AIDS Conference, 6/28-7/3, 1998, Geneva. Abstract.
40. Jarrousse B, Cohen P, Soussan P, et al. Efficacy and hepatic tolerance of treatment with protease inhibitors in HIV and hepatitis C virus (HCV) co-infected patients. Presented at the 12th World AIDS Conference, 6/28-7/2, 1998, Geneva. Abstract.
41. Rodriguez-Resado R, Garcia-Samaniego J, Soriano V, et al. Hepatotoxicity after introduction of highly active antiretroviral therapy (HAART). Presented at the 12th World AIDS Conference, 6/28-7/2, 1998, Geneva. Abstract.
42. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatoxicity associated with antiretroviral therapy among HIV-infected adults: the role of protease inhibitors and hepatitis C infection. Presented at the 38th ICAAC annual meeting of the American Society for Microbiology, 9/24-27, 1998, San Diego, CA. Abstract.
43. Piroth L, Grappin M, Waldner A, et al. Discontinuation of antiprotease inhibitor therapy due to drug toxicity: study of a cohort of 309 patients. Presented at the 38th ICAAC annual meeting of the American Society for Microbiology, 9/24-27, 1998, San Diego, CA. Abstract.
44. Langmann P., Zilly M., Bienert A., et al. Hepatoxicity of ritonavir and saquinavir during therpay of HIV-infection in patients with chronic viral hepatitis. Hepatology. 28:1998;637A. Abstract.
45. Freiman J.P., Helfert K.E., Hamrell M.R., Stein D.S. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS. 7:1993;379-385.
46. Mauss S., Heintges R., Adams O., et al. Treatment of chronic hepatitis C with interferon-alpha in patients infected with the human immunodeficiency virus. Hepatogastroenterology. 42:1995;528-534.
47. Garcia-Samaniego J, Soriano V, Perez-Olmeda M, et al. Long-term response to interferon-therapy in HIV-infected patients with chronic hepatitis C. Presented at the 12th World AIDS Conference, 6/28-7/3, 1998, Geneva. Abstract.
48. Vogt M.W., Harshorn K.L., Furman P.A., et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science. 235:1987;1376-1379.
49. Japour A.J., Lertora J.J., Meehan M.P., et al. A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin patients with HIV-1 disease. J Acquir Immune Defic Syndr Hum Retrovirol. 13:1996;235-246.
50. Bernier R., Tremblay M., Tsoukas C., Bergeron M.G. Drug sensitivity of human immunodeficiency virus type 1 isolates after ribavirin therapy. J Infect Dis. 175:1997;176-178.
51. Poles M.A., Dieterich D.T., Schwarz E.D., et al. Liver biopsy findings in 501 patients infected with human immunodeficiency virus (HIV). J Acquir Immune Defic Syndr Hum Retrovirol. 11:1996;170-177.
52. Wong J.B., Bennett W.G., Koff R.S., Pauker S.G. Pretreatment evaluation of chronic hepatitis C risks, benefits and costs . JAMA. 280:1998;2088-2093.
53. Laskus T., Radkowshi M., Wang L.R., et al. Search for hepatitis C virus extrahepatic replication sites in patients with acquired immunodeficiency syndrome specific detection of negative-strand viral RNA in various tissues . Hepatology. 28:1998;1398-1401.
54. Stoll M, Tillman HL, Behrens G, et al. Response and toxicity of interferon-(IFN)-α-2a treatment in chronic hepatitis C (HCV) in HIV infected patients. Presented at the 12th World AIDS Conference, 6/28-7/2, 1998, Geneva. Abstract.
55. Rodriguez M. Interferon-α-2B treatment for chronic hepatitis in the AIDS spectrum: concomitant interferon-α-2B and protease inhibitors. Presented at the 12th World AIDS Conference, 6/28-7/2, 1998, Geneva. Abstract.
56. Gubertino G., Giorgi R., Magnami C., et al. Is alpha interferon-treatment for chronic hepatitis C also indicated in HIV+ patients? Abstract. Hepatology. 28:1998;473A.